PETVIVO HOLDINGS, INC. FEATURED IN NEW RESEARCH UPDATE
PetVivo Holdings, Inc. (OTCMKTS:PETV)
MINNEAPOLIS, MN, US, August 29, 2018 /EINPresswire.com/ — MINNEAPOLIS, MN—August 29, 2018- PetVivo Holdings, Inc. (OTCPINK:PETV), an emerging biomedical device company, is very pleased to announce that Marble Arch Research Inc., a leading independent equity research provider, has produced a new investment research report on the Company. The updated report provides an overview of recent events as well as a recent acquisition in the space which favorably impacts the company valuation relative to its peer group. The sponsored research update also carries a rating and a price target and can be accessed at www.MarbleArchUSA.com.
In the update report released today, Marble Arch Research notes that, “PetVivo Holdings continues to make all the right moves vis-à-vis its infrastructure, approach, target market, and product roadmap. This space is hot and PETV will benefit. One of the leaders in the veterinary space just acquired a veterinary diagnostics company for $1.9B, or 6.3x next year’s revenue. Our price target is based upon a 6x sales P/S multiple and affirmed by a Net Present Value (NPV) calculation. In our view, investors could be handsomely rewarded.”
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCPINK:PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes 17 animal and human therapeutics. A portfolio of 20 patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.
Forward-Looking Commercial Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.
Wes Hayne, CEO
PetVivo Holdings, Inc.
5251 Edina Industrial Blvd
Edina, MN 55439
CEO’s Direct Line:
Petvivo Holdings Inc
email us here